120 related articles for article (PubMed ID: 36702703)
1. The emerging role of cell cycle protein p53 expression by tumor cells and M2-macrophage infiltration in urinary bladder cancer.
Aljabery F; Shabo I; Saudi A; Holmbom M; Olson H; Jahnson S
Urol Oncol; 2023 Mar; 41(3):148.e9-148.e16. PubMed ID: 36702703
[TBL] [Abstract][Full Text] [Related]
2. M2-macrophage infiltration and macrophage traits of tumor cells in urinary bladder cancer.
Aljabery F; Olsson H; Gimm O; Jahnson S; Shabo I
Urol Oncol; 2018 Apr; 36(4):159.e19-159.e26. PubMed ID: 29288002
[TBL] [Abstract][Full Text] [Related]
3. The expression profile of p14, p53 and p21 in tumour cells is associated with disease-specific survival and the outcome of postoperative chemotherapy treatment in muscle-invasive bladder cancer.
Aljabery F; Shabo I; Gimm O; Jahnson S; Olsson H
Urol Oncol; 2018 Dec; 36(12):530.e7-530.e18. PubMed ID: 30539751
[TBL] [Abstract][Full Text] [Related]
4. Tumor-associated macrophages and Tregs influence and represent immune cell infiltration of muscle-invasive bladder cancer and predict prognosis.
Koll FJ; Banek S; Kluth L; Köllermann J; Bankov K; Chun FK; Wild PJ; Weigert A; Reis H
J Transl Med; 2023 Feb; 21(1):124. PubMed ID: 36793050
[TBL] [Abstract][Full Text] [Related]
5. Immune Cell-Associated Protein Expression Helps to Predict Survival in Muscle-Invasive Urothelial Bladder Cancer Patients after Radical Cystectomy and Optional Adjuvant Chemotherapy.
Taubert H; Eckstein M; Epple E; Jung R; Weigelt K; Lieb V; Sikic D; Stöhr R; Geppert C; Weyerer V; Bertz S; Kehlen A; Hartmann A; Wullich B; Wach S
Cells; 2021 Jan; 10(1):. PubMed ID: 33467469
[TBL] [Abstract][Full Text] [Related]
6. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
[TBL] [Abstract][Full Text] [Related]
7. The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure.
Lima L; Oliveira D; Tavares A; Amaro T; Cruz R; Oliveira MJ; Ferreira JA; Santos L
Urol Oncol; 2014 May; 32(4):449-57. PubMed ID: 24252833
[TBL] [Abstract][Full Text] [Related]
8. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness.
Shariat SF; Zlotta AR; Ashfaq R; Sagalowsky AI; Lotan Y
Mod Pathol; 2007 Apr; 20(4):445-59. PubMed ID: 17384651
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: immunohistochemical analysis of radical cystectomy specimens.
Tsuji M; Kojima K; Murakami Y; Kanayama H; Kagawa S
Br J Urol; 1997 Mar; 79(3):367-72. PubMed ID: 9117215
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy.
Liu A; Xue Y; Liu F; Tan H; Xiong Q; Zeng S; Zhang Z; Gao X; Sun Y; Xu C
Cancer Biomark; 2019; 26(3):281-289. PubMed ID: 31594208
[TBL] [Abstract][Full Text] [Related]
11. Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells.
Maniecki MB; Etzerodt A; Ulhøi BP; Steiniche T; Borre M; Dyrskjøt L; Orntoft TF; Moestrup SK; Møller HJ
Int J Cancer; 2012 Nov; 131(10):2320-31. PubMed ID: 22362417
[TBL] [Abstract][Full Text] [Related]
12. p53 expression in patients with advanced urothelial cancer of the urinary bladder.
Shariat SF; Bolenz C; Karakiewicz PI; Fradet Y; Ashfaq R; Bastian PJ; Nielsen ME; Capitanio U; Jeldres C; Rigaud J; Müller SC; Lerner SP; Montorsi F; Sagalowsky AI; Cote RJ; Lotan Y
BJU Int; 2010 Feb; 105(4):489-95. PubMed ID: 19659466
[TBL] [Abstract][Full Text] [Related]
13. Tumor‑infiltrating M2 macrophages driven by specific genomic alterations are associated with prognosis in bladder cancer.
Xue Y; Tong L; LiuAnwei Liu F; Liu A; Zeng S; Xiong Q; Yang Z; He X; Sun Y; Xu C
Oncol Rep; 2019 Aug; 42(2):581-594. PubMed ID: 31233191
[TBL] [Abstract][Full Text] [Related]
14. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
[TBL] [Abstract][Full Text] [Related]
15. Accumulation of nuclear p53 and tumor progression in bladder cancer.
Esrig D; Elmajian D; Groshen S; Freeman JA; Stein JP; Chen SC; Nichols PW; Skinner DG; Jones PA; Cote RJ
N Engl J Med; 1994 Nov; 331(19):1259-64. PubMed ID: 7935683
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of
Ecke TH; Kiani A; Schlomm T; Friedersdorff F; Rabien A; Jung K; Kilic E; Boström P; Tervahartiala M; Taimen P; Gleichenhagen J; Johnen G; Brüning T; Koch S; Roggisch J; Wirtz RM
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050010
[TBL] [Abstract][Full Text] [Related]
17. Expression of cell cycle-related molecular markers in patients treated with radical cystectomy for squamous cell carcinoma of the bladder.
Youssef RF; Shariat SF; Kapur P; Kabbani W; Ghoneim T; King E; Cockburn A; Mosbah A; Abol-Enein H; Ghoneim M; Lotan Y
Hum Pathol; 2011 Mar; 42(3):347-55. PubMed ID: 21111452
[TBL] [Abstract][Full Text] [Related]
18. [Radical cystectomy in the treatment of bladder cancer always in due time?].
May M; Braun KP; Richter W; Helke C; Vogler H; Hoschke B; Siegsmund M
Urologe A; 2007 Aug; 46(8):913-9. PubMed ID: 17676301
[TBL] [Abstract][Full Text] [Related]
19. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
Tzai TS; Tsai YS; Chow NH
Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
[TBL] [Abstract][Full Text] [Related]
20. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
